Preconception Cardiovascular Planning: What to Check Before You Try to Get Pregnant

Pregnancy produces a high-volume, low-resistance circulatory state that stress-tests the cardiovascular system: plasma volume increases 50%, cardiac output rises 30 to 50%, and heart rate climbs 10 to 20 beats per minute. The 2023 American Heart Association scientific statement on prepregnancy cardiovascular health (Lewey et al. 2023) established that women with uncontrolled hypertension, undiagnosed structural heart disease, or untreated metabolic dysfunction entering pregnancy face substantially higher risks of preeclampsia, preterm delivery, and maternal cardiac events. Preconception cardiovascular optimization represents the single highest-use intervention point for protecting both mother and child.

The best cardiac preparation for pregnancy happens before pregnancy. When she finally asked about her heart before trying to conceive, her cardiologist said: I am glad you’re here before the baby rather than during.

She was 34, with borderline blood pressure readings she had dismissed for years. Her internist had never flagged them as urgent. Her gynecologist had never connected them to pregnancy risk. Now, planning her first pregnancy, she sat in my office with a blood pressure of 146/94 mmHg, a TSH of 4.8 mIU/L, and a fasting glucose of 112 mg/dL. She had three modifiable risk factors that would have collided with pregnancy in the worst possible way. She came to me before the collision. Most women do not.

The Hemodynamic Stress Test You Cannot Fail

Pregnancy is not a passive state. It is a 40-week cardiovascular stress test that your body cannot pause or reschedule.

The physiology is specific and unforgiving. By week 6, plasma volume begins expanding. By week 24, it reaches 50% above baseline. Cardiac output rises 30 to 50% to meet the demands of the developing placenta. Heart rate increases 10 to 20 beats per minute. Systemic vascular resistance falls as blood vessels dilate under the influence of progesterone and relaxin. 5 / Solid

This high-volume, low-resistance state exposes every weakness in the cardiovascular system. A woman with pre-existing hypertension faces amplified vascular strain. A woman with undiagnosed mitral stenosis discovers her valve cannot handle the increased flow. A woman with occult coronary disease experiences demand ischemia for the first time.

The 2018 ESC Guidelines for cardiovascular disease in pregnancy (Regitz-Zagrosek et al. 2018) use the modified WHO maternal cardiovascular risk classification to stratify women into four categories. Class I carries minimal increased risk. Class IV, which includes severe pulmonary hypertension and severe systolic left ventricular dysfunction, carries prohibitive risk where pregnancy may be contraindicated entirely.

The critical insight: most women have never been classified. They enter pregnancy without knowing whether their cardiovascular system can handle the load.

Preconception planning is not about finding reasons to avoid pregnancy. It is about identifying the specific interventions that allow pregnancy to proceed safely. The woman with hypertension needs her blood pressure controlled. The woman with valvular disease needs her lesion quantified. The woman with metabolic syndrome needs her insulin resistance addressed.

The 2023 AHA scientific statement (Lewey et al. 2023) explicitly calls for prepregnancy cardiovascular risk assessment as a routine component of reproductive planning. This is not standard practice in most primary care or obstetric settings. It should be.

The Preconception Cardiovascular Panel

I use what I call The Preconception Cardiac Readiness Protocol. It consists of five domains: blood pressure, metabolic function, thyroid status, medication review, and structural assessment.

Blood Pressure. The target is below 140/90 mmHg, ideally below 130/80 mmHg. The CHAP trial (Tita et al. NEJM 2022) randomized 2,408 women with mild chronic hypertension to treatment targeting below 140/90 mmHg versus no treatment unless blood pressure exceeded 160/105 mmHg. The treatment group had a 52% reduction in severe preeclampsia (RR 0.48; 95% CI 0.36-0.64). 5 / Solid

This is not a subtle effect. It is a halving of one of the most dangerous pregnancy complications. And it requires nothing more than blood pressure control before and during pregnancy.

Metabolic Function. Fasting glucose should be below 100 mg/dL. HbA1c should be below 6.5% (48 mmol/mol) for women with known diabetes. The TODAY2 study (Diabetes Care 2021) showed that women with type 2 diabetes entering pregnancy with HbA1c above 6.5% had a 2.4-fold higher risk of a composite adverse outcome including preeclampsia, preterm birth, and large-for-gestational-age infant compared to those with HbA1c below 6.5%. 5 / Solid

Fasting insulin is equally important and less commonly measured. Insulin resistance predicts gestational diabetes, even when fasting glucose appears normal. A fasting insulin above 15 μIU/mL warrants intervention.

Thyroid Status. Target TSH below 2.5 mIU/L before conception. The American Thyroid Association consensus statement (Alexander et al. Thyroid 2017) established this threshold based on evidence linking higher TSH to miscarriage and impaired fetal neurodevelopment. A meta-analysis (Maraka et al. BMJ 2016) found TSH above 4.0 mIU/L associated with a 1.5 to 2-fold increased risk of pregnancy loss. 5 / Solid

Women with Hashimoto’s thyroiditis require special attention. Pregnancy increases levothyroxine requirements by 25 to 50% due to expanded plasma volume and increased binding proteins. The dose adjustment should begin at the confirmation of pregnancy, not at the first prenatal visit.

Medication Review. This is the domain where preconception planning saves the most acute harm.

Statins are Category X. Atorvastatin, rosuvastatin, simvastatin, and all other statins must stop at least three months before conception. The three-month washout allows complete clearance and time to assess lipid status off medication. The FDA Adverse Event Reporting System analysis (Bateman et al. BMJ 2015) identified a 1.5-fold increased risk of congenital anomalies with first-trimester statin exposure. 4 / Promising

ACE inhibitors and ARBs are contraindicated throughout pregnancy. Lisinopril, enalapril, losartan, valsartan, and all drugs in these classes cause fetal renal dysgenesis, oligohydramnios, and skull hypoplasia. They can be stopped when pregnancy is confirmed, but the best approach is to switch to pregnancy-compatible alternatives before conception.

Safe antihypertensive options in pregnancy include labetalol, nifedipine extended-release, and methyldopa. Labetalol is my first choice for women with chronic hypertension planning pregnancy.

Structural Assessment. Not every woman needs an echocardiogram before pregnancy. But specific indications warrant one: known murmur, history of rheumatic fever, family history of cardiomyopathy, symptoms of dyspnea or palpitations on exertion, or any prior cardiac imaging abnormality.

The echocardiogram answers three questions: Is there valvular disease that will worsen with increased volume? Is there left ventricular dysfunction that will decompensate with increased output? Is there pulmonary hypertension that makes pregnancy high-risk or contraindicated?

PCOS: The Metabolic Amplifier

Polycystic ovary syndrome affects 8 to 13% of reproductive-age women. It is not primarily a reproductive disorder. It is a metabolic disorder with reproductive consequences.

Women with PCOS carry a 2.5-fold higher risk of preeclampsia independent of obesity (Palomba et al. Hum Reprod Update 2015). They have higher rates of gestational diabetes, preterm delivery, and cesarean section. These risks are mediated by insulin resistance, chronic low-grade inflammation, and endothelial dysfunction. 5 / Solid

The preconception opportunity: PCOS-related risks are modifiable.

Metformin, continued through pregnancy, reduces gestational diabetes risk in women with PCOS. Weight reduction of 5 to 10% before conception improves insulin sensitivity and reduces preeclampsia risk. Lipid optimization matters even in women too young for traditional cardiovascular risk assessment.

Women don’t die from what they have. Women die from what they hold.

The woman with PCOS holds insulin resistance, inflammation, and vascular dysfunction beneath normal-appearing vital signs. Pregnancy amplifies what she holds. Preconception planning reveals it before amplification.

The specific panel I order for women with PCOS planning pregnancy: fasting glucose, fasting insulin, HbA1c, complete lipid panel with calculated LDL, TSH, and free T4. Elevated fasting insulin above 15 μIU/mL or HOMA-IR above 2.5 triggers lifestyle intervention and consideration of metformin.

The Medication Transition Checklist

I give every woman planning pregnancy a one-page medication review. Here is what it contains:

Must Stop Before Conception:

• Statins (all): Stop 3 months before conception
• Warfarin: Stop and bridge to low-molecular-weight heparin if anticoagulation required
• Methotrexate: Stop 3 months before conception (both women and partners)

Must Stop at Confirmed Pregnancy:

• ACE inhibitors (lisinopril, enalapril, ramipril, others)
• ARBs (losartan, valsartan, irbesartan, others)
• Spironolactone

Safe to Continue:

• Labetalol
• Nifedipine extended-release
• Methyldopa
• Metformin
• Levothyroxine (increase dose 25-50% when pregnancy confirmed)
• Low-dose aspirin (81 mg, often recommended for preeclampsia prevention)

Requires Individual Assessment:

• Beta-blockers other than labetalol (atenolol associated with fetal growth restriction)
• Calcium channel blockers other than nifedipine
• Anticonvulsants (valproate contraindicated; levetiracetam and lamotrigine preferred)

This checklist prevents two scenarios I see repeatedly in practice. First: the woman who discovers she is pregnant while still on an ACE inhibitor because no one discussed this before conception. Second: the woman who stops all her cardiac medications “to be safe” and enters pregnancy with uncontrolled hypertension.

Neither scenario serves the mother or the fetus. The transition plan does.

Thyroid and Hashimoto’s: The Hidden Pregnancy Risk

Thyroid dysfunction is the most commonly missed preconception cardiovascular risk factor.

Hypothyroidism increases preeclampsia risk, impairs fetal neurodevelopment, and raises miscarriage rates. Hyperthyroidism increases atrial fibrillation risk, worsens heart failure in women with structural disease, and can cause fetal thyrotoxicosis.

Hashimoto’s thyroiditis deserves specific attention. It is the most common cause of hypothyroidism in reproductive-age women. It is autoimmune. It is progressive. And it is undertreated.

A woman with Hashimoto’s may have a “normal” TSH of 3.8 mIU/L that is inadequate for pregnancy. The preconception target is below 2.5 mIU/L. The dose increase should begin immediately when pregnancy is confirmed, not at the first prenatal appointment at 8 or 10 weeks.

The cardiac connection: Hashimoto’s patients have higher rates of subclinical atherosclerosis, impaired endothelial function, and elevated inflammatory markers. The autoimmune process does not stay confined to the thyroid. It creates systemic vascular effects that pregnancy amplifies.

Every woman with Hashimoto’s planning pregnancy should have TSH, free T4, and TPO antibodies checked before conception. If TSH is above 2.5 mIU/L, levothyroxine should be adjusted. If TPO antibodies are elevated, she should understand that levothyroxine requirements will increase substantially during pregnancy.

Preeclampsia Risk Stratification

Preeclampsia affects 3 to 5% of pregnancies. It is not random. It is predictable.

The ACOG and USPSTF recommend low-dose aspirin (81 mg daily) for preeclampsia prevention in women with high-risk factors. High-risk factors include: previous preeclampsia, chronic hypertension, type 1 or type 2 diabetes, renal disease, autoimmune disease, and multifetal gestation.

Moderate-risk factors include: first pregnancy, maternal age above 35, BMI above 30, family history of preeclampsia, sociodemographic factors, and personal history factors such as prior adverse pregnancy outcomes.

A woman with one high-risk factor or two or more moderate-risk factors should start low-dose aspirin at 12 to 16 weeks gestation. The preconception visit identifies these factors before the window closes.

The Preeclampsia Risk Framework I use stratifies women into three tiers:

Tier 1: Standard Risk. No high-risk or moderate-risk factors. No aspirin indicated. Standard prenatal monitoring.

Tier 2: Elevated Risk. One high-risk factor or two or more moderate-risk factors. Low-dose aspirin starting at 12 to 16 weeks. Consider serial blood pressure monitoring.

Tier 3: High Risk. Previous preeclampsia with severe features, chronic hypertension with target organ damage, or multiple high-risk factors. Low-dose aspirin, cardiology co-management, and possible antenatal surveillance.

This stratification happens at the preconception visit, not after the pregnancy has already started.

The Team-Based Model

The 2021 JACC scientific statement on team-based care for women with cardiovascular disease in pregnancy (Lindley et al. 2021) established the cardio-obstetric care model. It involves coordination between cardiology, maternal-fetal medicine, anesthesiology, and nursing.

For most women, this level of coordination is unnecessary. But for women with structural heart disease, cardiomyopathy, pulmonary hypertension, or complex arrhythmias, it is essential.

The preconception visit determines which track a woman is on. Standard obstetric care is appropriate for most women. Cardio-obstetric co-management is necessary for a subset. The distinction must be made before pregnancy, not discovered during it.

I refer women to maternal-fetal medicine preconception when they have: known structural heart disease, ejection fraction below 50%, pulmonary hypertension of any degree, prior peripartum cardiomyopathy, mechanical heart valve, or complex congenital heart disease.

The preconception consultation establishes the delivery plan, the monitoring schedule, and the contingency protocols. It removes surprise from the equation.

The Folic Acid Foundation

Cardiovascular planning does not replace standard preconception care. It supplements it.

All women planning pregnancy should take 400 to 800 mcg of folic acid daily starting at least three months before conception. This reduces neural tube defects by approximately 70%.

Women with diabetes, obesity, or prior neural tube defect-affected pregnancy should take 4 mg (4,000 mcg) daily under physician supervision.

The folic acid requirement is non-negotiable. It is the baseline on which cardiovascular optimization builds.

Your Preconception Cardiovascular Checklist

The preconception visit should accomplish five objectives:

1. Blood pressure documented. If above 130/80 mmHg, lifestyle intervention. If above 140/90 mmHg, medication with pregnancy-safe agents.

2. Metabolic panel complete. Fasting glucose, fasting insulin, HbA1c if indicated, complete lipid panel. Abnormalities addressed before conception.

3. Thyroid status confirmed. TSH below 2.5 mIU/L. Dose adjustment if needed.

4. Medication review documented. Contraindicated medications stopped or transitioned. Safe alternatives in place.

5. Risk stratification complete. WHO maternal cardiovascular risk class assigned. Preeclampsia risk tier identified. Care pathway established.

This checklist takes one visit. It can prevent complications that unfold over 40 weeks.

At your next appointment with your primary care physician or gynecologist, bring this list. Ask for these five assessments by name. If you have known cardiac disease, request referral to cardiology before attempting conception. If you have PCOS, diabetes, or chronic hypertension, request referral to maternal-fetal medicine for preconception counseling.

The best cardiac preparation for pregnancy is the preparation that happens before pregnancy begins.

Frequently Asked Questions

How far in advance should I see a cardiologist before trying to conceive?

The minimum is three months before attempting conception. This allows time for medication transitions, including the three-month statin washout period. It provides opportunity for blood pressure optimization if readings are elevated. It permits metabolic correction including HbA1c reduction in women with diabetes. Women with known heart conditions, including structural valve disease, prior cardiomyopathy, arrhythmias, or congenital heart disease, should begin preconception planning six to twelve months before attempting pregnancy. This extended timeline allows for complete cardiac evaluation, establishment of a cardio-obstetric team if needed, and documentation of a delivery plan before conception occurs.

Which heart medications must I stop before getting pregnant?

Three medication classes require preconception discontinuation. Statins, including atorvastatin, rosuvastatin, simvastatin, and pravastatin, are Category X and require a three-month washout before conception. ACE inhibitors, including lisinopril, enalapril, and ramipril, cause fetal renal damage and should be stopped before conception or immediately upon pregnancy confirmation. ARBs, including losartan, valsartan, and irbesartan, carry the same risks as ACE inhibitors. The ideal approach is to transition to labetalol or nifedipine extended-release before conception so you enter pregnancy already on safe medications with documented blood pressure control.

What blood pressure should I achieve before trying to conceive?

Target blood pressure below 140/90 mmHg at minimum, with best target below 130/80 mmHg. The CHAP trial demonstrated that treating chronic hypertension to below 140/90 mmHg during pregnancy reduced severe preeclampsia by 52% compared to only treating when blood pressure exceeded 160/105 mmHg. Women entering pregnancy with uncontrolled hypertension face dramatically higher risks of preeclampsia, placental abruption, fetal growth restriction, and preterm delivery. Blood pressure control before conception provides a buffer against the normal blood pressure changes of pregnancy and reduces the starting point from which any pregnancy-related increase occurs.

Does PCOS affect my heart risk during pregnancy?

Yes, substantially. PCOS confers a 2.5-fold higher risk of preeclampsia independent of obesity and BMI. It increases rates of gestational diabetes, preterm delivery, and cesarean section. The mechanism involves insulin resistance, chronic inflammation, and endothelial dysfunction that pregnancy amplifies. Women with PCOS should undergo metabolic screening before conception including fasting insulin, fasting glucose, HbA1c, and lipid panel. A fasting insulin above 15 μIU/mL or HOMA-IR above 2.5 indicates insulin resistance requiring intervention. Metformin may be started preconception and continued through pregnancy to reduce gestational diabetes risk.

What thyroid level do I need before getting pregnant?

Target TSH below 2.5 mIU/L before conception. This threshold is lower than the standard upper limit of normal for non-pregnant adults because of the critical role thyroid hormone plays in early fetal brain development. A TSH above 4.0 mIU/L carries a 1.5 to 2-fold increased risk of miscarriage. Women with Hashimoto’s thyroiditis require particular attention because their levothyroxine requirements typically increase by 25 to 50 percent during pregnancy due to expanded plasma volume and increased binding proteins. The dose increase should begin immediately upon pregnancy confirmation, not at the first prenatal visit weeks later.